CY1108843T1 - 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων - Google Patents

3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων

Info

Publication number
CY1108843T1
CY1108843T1 CY20091100221T CY091100221T CY1108843T1 CY 1108843 T1 CY1108843 T1 CY 1108843T1 CY 20091100221 T CY20091100221 T CY 20091100221T CY 091100221 T CY091100221 T CY 091100221T CY 1108843 T1 CY1108843 T1 CY 1108843T1
Authority
CY
Cyprus
Prior art keywords
schizophrenia
cis
treatment
dimrodetretravenasine
psychologies
Prior art date
Application number
CY20091100221T
Other languages
Greek (el)
English (en)
Inventor
Andrew John Duffield
Jean Elisabeth Yarrow
Original Assignee
Biovail Laboratories International (Barbados) Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0516167.4A external-priority patent/GB0516167D0/en
Priority claimed from GB0516790A external-priority patent/GB0516790D0/en
Application filed by Biovail Laboratories International (Barbados) Srl filed Critical Biovail Laboratories International (Barbados) Srl
Publication of CY1108843T1 publication Critical patent/CY1108843T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20091100221T 2005-08-06 2009-02-26 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων CY1108843T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0516167.4A GB0516167D0 (en) 2005-08-06 2005-08-06 Pharmaceutical compounds
GB0516790A GB0516790D0 (en) 2005-08-16 2005-08-16 Pharmaceutical compounds
EP06765238A EP1855677B1 (en) 2005-08-06 2006-08-04 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses

Publications (1)

Publication Number Publication Date
CY1108843T1 true CY1108843T1 (el) 2014-07-02

Family

ID=37400949

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100221T CY1108843T1 (el) 2005-08-06 2009-02-26 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων

Country Status (20)

Country Link
US (1) US20110257220A1 (enExample)
EP (2) EP1855677B1 (enExample)
JP (1) JP2009504622A (enExample)
KR (1) KR20080033500A (enExample)
AT (2) ATE534391T1 (enExample)
AU (1) AU2006277753B2 (enExample)
CA (1) CA2620960A1 (enExample)
CY (1) CY1108843T1 (enExample)
DE (1) DE602006004009D1 (enExample)
DK (1) DK1855677T3 (enExample)
ES (1) ES2318771T3 (enExample)
HR (1) HRP20090074T3 (enExample)
MX (1) MX2008001549A (enExample)
NZ (1) NZ566011A (enExample)
PL (1) PL1855677T3 (enExample)
PT (1) PT1855677E (enExample)
RS (1) RS50807B (enExample)
RU (1) RU2407743C2 (enExample)
SI (1) SI1855677T1 (enExample)
WO (1) WO2007017654A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2081929T3 (da) 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse
US8008500B2 (en) 2007-06-08 2011-08-30 General Electric Company Intermediates useful for making tetrabenazine compounds
US8053578B2 (en) 2007-11-29 2011-11-08 General Electric Company Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
US20120003330A1 (en) 2010-06-01 2012-01-05 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
EP2694573B1 (en) 2011-04-01 2020-05-27 3M Innovative Properties Company Films comprising triazine-based ultraviolet absorbers
KR20160111999A (ko) 2014-01-27 2016-09-27 오스펙스 파마슈티칼스, 인코포레이티드 소포성 모노아민 수송체 2의 벤조퀴놀린 억제제
US9782398B2 (en) * 2014-02-07 2017-10-10 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof
DK3368534T3 (da) 2015-10-30 2021-02-15 Neurocrine Biosciences Inc Valbenazin-ditosylat og polymorfer deraf
DK3394057T3 (da) 2015-12-23 2022-04-11 Neurocrine Biosciences Inc Syntetisk fremgangsmåde til fremstilling af (S)-(2R,3R,11BR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11B-hexahydro-1H-pyrido[2,1,-A]isoquinolin-2-yl 2-amino-3-methylbutanoat-di(4-methylbenzensulfonat)
TW202515564A (zh) * 2016-12-02 2025-04-16 美商紐羅克里生物科學有限公司 戊苯那嗪(valbenazine)於治療精神分裂症或情感性精神分裂症之用途
KR20230170136A (ko) 2017-01-27 2023-12-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705305D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830993A (en) 1958-04-15 Quinolizine derivatives
US2843591A (en) 1958-07-15 Method for preparing same
CA2058640A1 (en) * 1991-01-25 1992-07-26 Richard R. Scherschlicht Tricyclic pyridone derivative
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
FR2770215B1 (fr) * 1997-10-28 2000-01-14 Pf Medicament Derives d'aminomethyl-benzo[a]quinolizidine, leur preparation et leur application en therapeutique pour les maladies neurodegeneratives
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
MX2008001549A (es) 2008-04-04
CA2620960A1 (en) 2007-02-15
EP2050451B1 (en) 2011-11-23
EP2050451A1 (en) 2009-04-22
EP1855677A1 (en) 2007-11-21
AU2006277753B2 (en) 2011-11-10
WO2007017654A1 (en) 2007-02-15
RU2008108623A (ru) 2009-09-20
DK1855677T3 (da) 2009-02-09
EP1855677B1 (en) 2008-12-03
AU2006277753A1 (en) 2007-02-15
ATE415968T1 (de) 2008-12-15
DE602006004009D1 (de) 2009-01-15
US20110257220A1 (en) 2011-10-20
HRP20090074T3 (en) 2009-04-30
SI1855677T1 (sl) 2009-04-30
KR20080033500A (ko) 2008-04-16
RS50807B (sr) 2010-08-31
PT1855677E (pt) 2009-01-13
ES2318771T3 (es) 2009-05-01
RU2407743C2 (ru) 2010-12-27
ATE534391T1 (de) 2011-12-15
NZ566011A (en) 2011-01-28
JP2009504622A (ja) 2009-02-05
PL1855677T3 (pl) 2009-07-31
HK1111083A1 (en) 2008-08-01

Similar Documents

Publication Publication Date Title
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
CY1118523T1 (el) Πεπτιδικες ενωσεις για την θεραπεια του ανθεκτικου status epilepticus
CY1110247T1 (el) Παραγωγα βενζοκιναζολινης και η χρηση τους στην θεραπεια των διαταραχων των οστων
MY148491A (en) FUSED BICYCLIC mTOR INHIBITORS
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
CY1110835T1 (el) Διφαινυλ παραγωγα και η χρηση τους στη θεραπεια της ηπατιτιδας c
CY1115426T1 (el) 1,3-δισυποκατεστημενα παραγωγα ιμιδαζολιδιν-2-ονης ως αναστολεις toy cyp 17
CY1111437T1 (el) Τετραϋδροπυρρολοπυριμιδινοδιονες και η χρηση τους ως αναστολεων της ανθρωπινης ουδετεροφιλης ελαστασης
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
CY1113108T1 (el) Μεσυλικο προφαρμακου λεβοντοπα, συνθεσεις αυτου, και χρησεις αυτου
CY1113766T1 (el) Παραγωγα ινδολιδονης για την θεραπεια ή προληψη ινωτικων ασθενειων
CY1109656T1 (el) Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης
CY1108729T1 (el) 3,11b-cis-διυδpotetpabenazinh για την θεραπευτικη αντιμετωπιση μιας πολλαπλασιαστικης νοσου ή φλεγμονωδους παθησης
NO20091955L (no) Antivirale sammensetninger, og fremgangsmater for anvendelse
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
SE0301650D0 (sv) Novel compounds
EA200870584A1 (ru) Пролекарства пенема
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
CY1109803T1 (el) Φαρμακευτικες συνθεσεις που βασιζονται σε ανταγωνιστες νκ2 για παιδιατρικη χρηση
MX2010001304A (es) Compuestos terapeuticos.
TW200621260A (en) Selected fused heterocyclics and uses thereof
DK1713438T3 (da) Medicinsk sæbe